Patients have a right to decline or withdraw LVADs. Informed consent and shared decision making is not easy, however, with treatments that are high risk, high reward.
AMA J Ethics. 2019;21(5):E394-400. doi:
10.1001/amajethics.2019.394.
Despite challenges of decision making for unrepresented patients, few laws or policy statements offer solutions. This article offers 5 key things to do.
AMA J Ethics. 2019;21(7):E582-586. doi:
10.1001/amajethics.2019.582.
Physicians, committees, and guardians all make decisions for unrepresented patients in the US. This article considers a “tiered” approach as an alternative.
AMA J Ethics. 2019;21(7):E587-593. doi:
10.1001/amajethics.2019.587.
Case-based teaching, longitudinal application, and training in ethical deliberation can better prepare physicians to responsibly prescribe and manage opioids.
AMA J Ethics. 2019;21(8):E636-641. doi:
10.1001/amajethics.2019.636.
When patients are unable to express their wishes and do not have surrogates or advance directives, which and whose values should inform decision making for them? We discuss ethical complexities of caring for unrepresented patients.